Construction and characterization of a novel DNA vaccine that is potent antigen-specific tolerizing therapy for experimental arthritis by increasing CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines

Vaccine

Volumn 27, Issue 5, 2009, Pages 690-700

  Xinqiang, Song ^a   Fei, Liang ^a   Nan, Liu ^a   Yuan, Luo ^a   Hong, Xue ^a   Fang, Yuan ^a   Liuxin, Tan ^a   Yuying, Sun ^a   Caixi, Xi ^a   Yongzhi, Xi ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Chicken type II collagen; Collagen induced arthritis; Immunotherapy; Rheumatoid arthritis; Therapeutic vaccine; Vaccinotherapy

Indexed keywords

COLLAGEN TYPE 2; DNA VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 4; METHOTREXATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; FEMALE; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECOMBINANT PLASMID; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TH1 CELL; TH2 CELL; VACCINE PRODUCTION;

ANIMALS; ARTHRITIS, RHEUMATOID; CHICKENS; COLLAGEN TYPE II; CYTOKINES; FEMALE; IMMUNE TOLERANCE; INFLAMMATION; JOINTS; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS; VACCINES, DNA;

EID: 58249113108     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.090     Document Type: Article

References (61)

1. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 423 6937 (2003) 356-361
2. Wildbaum G., Nahir M.A., and Karin N. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 19 November (5) (2003) 679-688
3. Sinha A.A., Lopez M.T., and McDevitt H.O. Autoimmune diseases: the failure of self tolerance. Science 248 (1990) 1380-1388
4. O'Garra A., and Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 10 (2004) 801-805
5. Feldmann M. Pathogenesis of arthritis: recent research progress. Nat Immunol 2 (2001) 771-773
6. Friend D.S., Gurish M.F., and Benoist C. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297 (2002) 1689-1692
7. Liew F.Y., and McInnes I.B. A fork in the pathway to inflammation and arthritis. Nat Med 11 (2005) 601-602
8. von Herrath M.G., and Harrison L.C. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 3 (2003) 223-232
9. Hirano T. Revival of the autoantibody model in rheumatoid arthritis. Nat Immunol 3 (2002) 342-344
10. Steinman L. Immune therapy for autoimmune diseases. Science 305 (2004) 212-216
11. Rodan G.A., and John Martin T. Therapeutic approaches to bone diseases. Science 289 (2000) 1508-1514
12. Feldmann M., and Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 435 (2005) 612-619
13. Feldmann M., and Maini R.N. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9 (2003) 1245-1250
14. Mayer L., and Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol 4 (2004) 407-419
15. Mainni R.N., and Taylor P.C. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 51 (2000) 207-229
16. Xu H., and Xi Y.Z. Perspectives in gene therapy for autoimmune diseases. Nat Med J China 86 (2006) 933-935
17. Bird L. New drug for autoimmune diseases. Nat Rev Immunol 5 (2005) 748-1748
18. Edwards J.C.W., and Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6 (2006) 394-403
19. Prockop D.J., and Kivirikko K.I. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 64 (1995) 403-434
20. Hueber W., Kidd B.A., and Tomooka B.H. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 52 (2005) 2645-2655
21. Kim W.U., Cho M.L., and Jung Y.O. Type II collagen autoimmunity in rheumatoid arthritis. Am J Med Sci 327 (2004) 202-211
22. Williams R.O. Collagen-induced arthritis as a model for rheumatoid arthritis. Methods Mol Med 98 (2004) 207-216
23. Trentham D.E., Dynesius-Trentham R.A., and Orav E.J. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261 (1993) 1727-1730
24. Barnett M.L., Combitchi D., and Trentham D.E. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 39 (1996) 623-628
25. Barnett M.L., Kremer J.M., and St Clair E.M. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 41 (1998) 290-297
26. Sieper J., Kary S., and Sorensen H. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum 39 (1996) 41-51
27. McKown K.M., Carbone L.D., and Kaplan S.B. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum 42 (1999) 1204-1208
28. Garren H., Ruiz P.J., and Watkins T.A. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 15 (2001) 15-22
29. Ruiz P., Garren H., and Ruiz I.U. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. J Immunol 162 (1999) 3336-3341
30. Robinson W.H., Fontoura P., and Lee B.J. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 21 (2003) 1033-1039
31. Bot A., Smith D.J., and Bot S. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 167 (2001) 2950-2955
32. Balasa B., Boehm B.O., and Fortnagel A. Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection. Clin Immunol 99 (2001) 241-252
33. Ho P.P., Higgins J.P., and Kidd B.A. Tolerizing DNA vaccines for autoimmune arthritis. Autoimmunity 39 (2006) 675-682
34. Onodera S., Ohshima S., and Tohyama H. A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum 56 February (2) (2007) 521-530
35. Xi C., Liu N., and Liang F. Molecular cloning, characterization and localization of chicken type II procollagen gene. Gene 366 (2006) 67-76
36. Gamble B.M., Gallaqher P.A., and Shoemaker J.A. An investigation of the chemical stability of arsenosugars in simulated gastric juice and acidic environments using IC-ICP-MS and IC-ESI-MS/MS. Analyst 127 (2002) 781-785
37. Yan J.X., Walt R., and Berkelman T. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization mass spectrometry. Electrophoresis 21 (2000) 3666-3672
38. Rosloniec E.F., Kang A.H., and Myers L.K. Collagen-induced arthritis. In: Coico R., and Shevach E. (Eds). Current protocols in immunology (1997), Wiley & Sons, New York 1-24
39. Morgan S.L., Baggott J.E., and Bernreuter W.K. MTX affects inflammation and tissue destruction differently in the rat AA model. J Rheumatol 28 July (7) (2001) 1476-1481
40. Cuzzocrea S., Mazzon E., and di Paola R. Synergistic interaction between methotrexate and a superoxide dismutase mimetic: pharmacologic and potential clinical significance. Arthritis Rheum 52 (2005) 3755-3760
41. Paimela L., Laasonen L., and Helve T. Comparison of the original and the modified Larsen methods and the Sharp method in scoring radiographic progression in early rheumatoid arthritis. J Rheumatol 25 (1998) 1063-1066
42. Upham J.W., Lundahl J., and Liang H. Simplified quantitation of myeloid dendritic cells in peripheral blood using flow cytometry. Cytometry 40 (2000) 50-59
43. Pace J.M., Kuslich C.D., and Willing M.C. Disruption of one intra-chain disulphide bond in the carboxyl-terminal propeptide of the proalpha1(I) chain of type I procollagen permits slow assembly and secretion of overmodified, but stable procollagen trimers and results in mild osteogenesis imperfecta. J Med Genet 38 (2001) 443-449
44. Pakkanen O., Hamaanen E.-R., and Kivirikko K.I. Assembly of stable human type I and III collagen molecules from hydroxylated recombinant chains in the yeast Pichia pastoris. Effect of an engineered C-terminal oligomerization domain foldon. J Biol Chem 278 (2003) 32478-32483
45. Kivirikko K.I., Myllyla R., and Pihlajaniemi T. Protein hydroxylation: prolyl 4-hydroxylase, an enzyme with four cosubstrates and a multifunctional subunit. FASEB J (1989) 1609-1617
46. Myers L.K., Myllyharju J., and Nokelainen M. Relevance of posttranslational modifications for the arthritogenicity of type II collagen. J Immunol 172 (2004) 2970-2975
47. Xi CX, Tan LX, Sun YP, et al. A novel non-hydroxylated and non-glycosylated recombinant tolerogenic epitope peptide derived from chicken type II collagen is more potent against collagen-induced arthritis. Mol Immunol 2008, in press.
48. Borchers A.T., Keen C.L., and Cheema G.S. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum 34 (2004) 465-483
49. Kapral T., Stamm T., and Machold K.P. Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. Arthritis Res Ther 8 (2006) R46
50. Williams P.J., Jones R.H., and Rademacher T.W. Correlation between IgG anti-type II collagen levels and arthritic severity in murine arthritis. Autoimmunity 27 (1998) 201-207
51. Hackstein H., and Thomson A.W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 4 (2004) 24-35
52. Cremer M.A., Rosloniec E.F., and Kang A.H. The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J Mol Med 76 (1998) 275-288
53. Kim W.U., Yoo W.H., and Park W. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol 27 (2000) 575-581
54. Myllyharju J., Nokelainen M., Vuorela A., and Kivirikko K.I. Expression of recombinant human type I-III collagens in the yeast Pichia pastoris. Biochem Soc Trans 28 (2000) 353-357
55. Wu H.Y., and Weiner H.L. Oral tolerance. Immunol Res 28 (2003) 265-284
56. Steinmam L. Immune therapy for autoimmune diseases. Science 305 (2004) 212-216
57. +T cell responses: the alternative approaches. Annu Rev Immunol 15 (2004) 297-322
58. Sercarz E.E. Arraying autoimmunity treatment. Nat Biotechnol 21 (2003) 1017-1019
59. Platten M., Ho P.P., and Youssef S. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science (2006) 310850-310855
60. Lu L.F., Lind E.F., and Gondek D.C. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442 (2006) 997-1002
61. Bettelli E., Carrier Y., and Gao W. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441 (2006) 235-238